Journal article
Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers
LC Walker, N Waddell, A Ten Haaf, S Grimmond, AB Spurdle
Breast Cancer Research and Treatment | SPRINGER | Published : 2008
Abstract
Germline mutations in BRCA1 or BRCA2 confer an increased lifetime risk of developing breast or ovarian cancer, but variable penetrance suggests that cancer susceptibility is influenced in part by modifier genes. Microarray expression profiling was conducted for 69 irradiated lymphoblastoid cell lines derived from healthy controls, or from cancer-affected women with a strong family history of breast and ovarian cancer carrying pathogenic mutations in BRCA1 or BRCA2, or with no BRCA1/2 mutations (BRCAX). Genes discriminating between BRCA1, BRCA2 or BRCAX and controls were stratified based on irradiation response and/or cell cycle involvement. Gene lists were aligned against genes tagged with s..
View full abstractGrants
Awarded by National Breast Cancer Foundation
Funding Acknowledgements
We thank Sue Healey for providing assistance with BIC nomenclature and classifications, and David Hunter and Jonathan Beesley for helpful comments. We would like to thank all the Australian Red Cross Blood Services donors who participated as healthy controls in this study, Rachelle Morris and the staff at the Australian Red Cross Blood Services for their assistance with the collection of risk factor information and blood samples, and Helene Holland for data management, Mary-Anne Kedda, Joanne Young, Melanie Higgins, Kimberly Hinze, Robert Smith, Judith Clements, Melissa Barker, Rebecca Magson, Genevieve Birney and other members of the Molecular Cancer Epidemiology Laboratory, for their assistance with collection and processing of Australian Red Cross Blood Services blood samples. We thank Denis Moss for access to LCLs from controls recruited through the QIMR. We also wish to thank Heather Thorne, Eveline Niedermayr, Jan Groves, Amber Williams, the kConFab mutation review committee, kConFab research nurses and staff, the heads and staff of the Family Cancer Clinics, and the Clinical Follow Up Study (funded by NHMRC grants 145684 and 288704) for their contributions to this resource, and the many families who contribute to kConFab. kConFab is supported by grants from the National Breast Cancer Foundation, the National Health and Medical Research Council (NHMRC) and by the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania and South Australia, and the Cancer Foundation of Western Australia. This research was supported by a grant from the Susan G. Komen Breast Cancer Foundation, and the NHMRC. LCW was supported by funding from NHMRC, NW was supported by funding from the National Breast Cancer Foundation, SMG is an NMHRC Senior Research Fellow, and ABS is a recipient of an NHMRC Career Development Award.